Skip to main content
Back to bills
HR 1051119th CongressIntroducedHealth

To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of a...

Introduced: 2/6/2025

Sponsor: Rep. Budzinski, Nikki [D-IL-13] (D-IL)

Bill Details

Bill Type

HRHouse Bill

Congress

119th Congress (2025–2026)

Introduced

February 6, 2025

Latest Action

Referred to the House Committee on Energy and Commerce. (2/6/2025)

AI Bill Summary

Click "Generate Summary" to create an AI-powered analysis of this bill.

Ask This Bill a Question

Use AI to get answers about this bill's content, provisions, and impact.

Try asking:

Roll Call Votes

No roll call votes found for this bill.

This bill may not have been voted on yet.

HR 1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. - HowCongressVotes